Translational Research Program
Supports translational research in Primary Immunodeficiency to turn basic scientific discoveries into clinical advances, improving diagnosis, therapies, and patient outcomes.
Funder: Jeffrey Modell Foundation
Due Dates: March 13, 2026 (Letter of Intent) | July 24, 2026 (Full application, invited only)
Funding Amounts: Up to $250,000 total over two years; max $125,000/year; direct costs only (no overhead)
Summary: Supports innovative translational research in Primary Immunodeficiency (PI) to bridge basic discoveries to clinical applications and improve patient outcomes.
Key Information: Only one active grant per investigator at a time; international and U.S. investigators eligible.
Description
This program funds innovative and novel investigations in Primary Immunodeficiency (PI), especially those that translate basic scientific discoveries into clinical advances. The aim is to deepen understanding of genotype-phenotype correlations, immune mechanisms, and to foster research that leads to better diagnosis, new therapies, and improved health and quality of life for people affected by PI. Projects with a clear translational impact and those that are otherwise difficult to advance without this award are strongly encouraged.
